Julian März | Research Group Leader
University of Zurich

Dr. Julian W. März, M.D., Ph.D., LL.M., J.S.D., studied law, medicine, and bioethics at the Universities of Zurich, Oxford, Munich, Regensburg, and Passau, as well as at the Institut d’Études Politiques (IEP) de Paris, and holds doctorates in law (Dr. iur., 07/2020), bioethics (Dr. sc. med., 01/2023), and medicine (Dr. med., 12/2023). He works at the intersection of pharmaceutical regulatory law and translational research ethics, with a particular focus on genomic and individualized medicines, artificial intelligence, and data-driven innovation in the pharmaceutical sector from an international perspective. He is currently a Senior Research Fellow at the University Research Priority Programme (URPP) Innovative Therapies in Rare Diseases (ITINERARE) and the Institute of Biomedical Ethics (IBME), University of Zurich, and Research Group Leader of the PRe_DICT Lab – Pharmaceutical Regulation & Digital Innovation for Clinical & Translational Research. He is also affiliated with the Digital Society Initiative (DSI) – Health, Ethics and Law and AI sections – and the Competence Center Medicine – Ethics – Law Helvetiae (MERH) at the University of Zurich. His academic teaching includes lectures on the governance of genomic medicines and AI in healthcare and the life sciences, including within the Master’s Program in Medicine and the Biomedical Entrepreneurship Program at the University of Zurich, and the Master of Public Health program at the University of Geneva. Before joining the University of Zurich in 2022, he worked at the German Cancer Research Centre (DKFZ) in Heidelberg and at the Centre for Law, Medicine and Life Sciences, University of Cambridge. In addition, he trained as a lawyer at Cleary Gottlieb Steen & Hamilton LLP and Hogan Lovells LLP and is licensed as a physician in Switzerland. In October 2024, he was appointed to the WHO Research Ethics Review Committee (WHO-ERC) by the WHO Director-General, and from April 2024 to April 2025, he served as Lead Scientific Advisor to the Swiss federal government for the review of the Federal Law on the Genetic Testing of Humans (GUMG). He also serves as lead advisor in regulatory law and research ethics for several international research consortia and clinical trials, both academia- and industry-sponsored, in the fields of genomic and individualized medicines, rare diseases, and digital innovation.